Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Meta Platforms Debt Financing Update with Citigroup Global Markets Limited
Meta Platforms, Inc. completed a multi-tranche offering of Senior Notes denominated in Euros across six different maturities ranging from 2031 to 2065. The offering includes €1.75B of 4.300% notes due 2031, €1.25B of 4.650% notes due 2033, €1.00B of 4.900% notes due 2035, €1.75B of 5.400% notes due 2038, €1.75B of 6.050% notes due 2044, and €1.50B of 6.400% notes due 2065. The notes were issued under a seventh supplemental indenture with U.S. Bank Trust Company as trustee.
Counterparty
Citigroup Global Markets Limited and Morgan Stanley & Co. International plc
Robinhood Ventures Fund II reported a net investment loss of $1.87 million for the six months ended September 30, 2026, with total assets growing significantly to $217.1 million following its IPO in August 2026. The fund's net asset value per share decreased from $24.72 to $23.21 during the period, primarily driven by organizational expenses and offering costs.
Tim VP, Risk & Compliance Claudio Creo Sells $18.9K of Stock
Claudio Creo, VP, Risk & Compliance, sold 5,000 shares of Tim S.A. at $3.77 a share, worth $18.9K in total on Nov 10, 2026. Shares held after the trade: 21,798 (+29.8%).
Rtw Investments LP, 10% Owner, bought 1,200,000 shares of Orchestra BioMed Holdings, Inc. at $5.00 a share, worth $6M in total on Nov 9, 2026. Shares held after the trade: 10,756,063 (+12.6%).
Ondas Inc. reported a significant revenue increase to $301.4 million for the nine months ended September 30, 2026, compared to $20.6 million in the prior year, primarily driven by acquisition activity. Despite a quarterly net loss of $64.7 million, the company achieved a net income of $206.9 million for the nine-month period, largely due to $583.4 million in other income.
Candel Therapeutics entered into a Second Amended and Restated Open Market Sale Agreement with Jefferies LLC to establish a new at-the-market (ATM) equity facility. The agreement allows the company to sell up to $50 million of common stock from time to time, in addition to the $50 million previously sold under a prior 2025 agreement.
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on bacteriophage-based therapies. As of November 6, 2026, the company had 37,192,632 shares of common stock outstanding and is classified as a non-accelerated filer and smaller reporting company.
For the nine months ended September 30, 2026, Xos, Inc. reported revenues of $21.5 million, a significant decrease from $40.8 million in the prior year period. The company incurred a net loss of $19.4 million for the first nine months of 2026, while its cash position decreased to $12.1 million as of September 30, 2026.
Newsmax Inc. reported a significant financial turnaround for the nine months ended September 30, 2026, achieving a net income of $15.9 million compared to a net loss of $96.5 million in the prior year period. This improvement was driven by a 27.6% increase in total revenues to $174.8 million and a substantial reduction in general and administrative expenses, which had been inflated in 2025 by one-time corporate matters.
For the nine months ended September 30, 2026, iAnthus reported net revenues of $107.2 million and a net loss of $41.9 million, compared to a net loss of $26.1 million in the prior year period. The company's balance sheet shows a significant shift in debt classification, with $208.7 million in long-term debt moving to current liabilities, contributing to a total shareholders' deficit of $143.5 million.
Caci International Insider Debora A. Plunkett Sells $152K of Stock
Debora A. Plunkett sold 235 shares of Caci International Inc at $646.31 a share, worth $152K in total on Nov 11, 2026. Shares held after the trade: 2,447 (-8.8%).
Nuveen Farmland REIT commenced operations in late 2026, completing its initial closing on September 1, 2026, with $34.7 million in proceeds and acquiring an initial portfolio of two assets. For the nine months ended September 30, 2026, the company reported a net loss of $607,000, primarily driven by general and administrative expenses as it established its investment platform.
Ionic Digital Inc. reported a significant shift in its business model, with digital infrastructure leasing revenue of $131.7 million for the nine months ended September 30, 2026, surpassing its cryptocurrency mining revenue. Despite a net loss of $30.9 million for the nine-month period, the company achieved a net income of $17.4 million in the third quarter, bolstered by a $73.2 million gain on the fair value of cryptocurrency assets.
Vivos Inc. reported a net loss of $2,746,628 for the nine months ended September 30, 2026, compared to a loss of $1,987,503 in the prior year period, driven largely by a $847,628 non-operating loss on share issuances. While revenues increased significantly to $101,368 from $43,627, the company continues to operate with a substantial accumulated deficit of over $91 million.
KALA BIO filed a Certificate of Amendment to effect a 1-for-30 reverse stock split of its common stock, effective November 13, 2026. The split will reduce the number of outstanding shares from approximately 19.3 million to approximately 644,659 to meet market requirements. Shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market on November 16, 2026.
Nektar Therapeutics reported third quarter 2026 financial results, highlighting a cash position of $952.9 million and the initiation of Phase 3 registrational trials for rezpegaldesleukin in atopic dermatitis. The company reported a net loss of $55.7 million on revenue of $9.4 million, with R&D expenses increasing to support its late-stage clinical programs.
Term
Q3 2026
“This was a pivotal quarter for Nektar as we moved rezpegaldesleukin quickly into Phase 3 development. We have now initiated all three global ZENITH AD registrational trials in atopic dermatitis and our global ZENITH AA registrational trial in alopecia areata is on track to begin in December, earlier than previously planned.”
Howard Robin, President and Chief Executive Officer of Nektar
INNOVATE Corp. reported a significant turnaround for the third quarter of 2026, with net income attributable to common stockholders of $15.8 million compared to a net loss of $9.4 million in the prior year. Revenue grew to $495.5 million for the quarter, driven by operations and a $32.9 million gain on the sale of a controlling interest in a subsidiary.
Beneficient received a deficiency notice from Nasdaq on November 5, 2026, because its market value of listed securities (MVLS) fell below the $35 million minimum requirement for 30 consecutive business days. The company has until May 4, 2027, to regain compliance by maintaining an MVLS of at least $35 million for at least ten consecutive business days. The notice has no immediate effect on the listing of the company's Class A common stock (BENF) or warrants (BENFW).
BRT Apartments Chairman of the Board Matthew J. Gould Buys $39.4K of Stock
Matthew J. Gould, Chairman of the Board, bought 3,000 shares of BRT Apartments Corp. at $13.14 a share, worth $39.4K in total on Nov 9, 2026. Shares held after the trade: 3,000.
Tapestry, Inc. held its 2026 Annual Meeting of Stockholders where eleven directors were elected to serve until the 2027 meeting. Stockholders also ratified Deloitte & Touche LLP as the independent auditor, approved executive compensation on an advisory basis, and approved a stockholder proposal regarding action by written consent.
Motorola Solutions Chairman and CEO Gregory Q. Brown Sells $13.2M of Stock
Gregory Q. Brown, Chairman and CEO, sold 25,000 shares of Motorola Solutions, Inc. at $521.30 to $529.73 a share (average $526.14) in 10 transactions, worth $13.2M in total on Nov 10, 2026. Shares held after the trade: 66,769 (-0.2%).
Armata Pharmaceuticals reported its third quarter 2026 financial results and provided an update on its AP-SA02 Phase 3 program. The company is finalizing study designs with the FDA and has completed engineering runs at its cGMP manufacturing facility to support the upcoming pivotal trial.
“We continue to advance toward our most important near-term objective: initiating the Phase 3 superiority study of AP-SA02. We have progressed from planning to establishing the operational infrastructure needed to execute a large, pivotal clinical study.”
Dr. Deborah Birx, Chief Executive Officer
“We believe the FDA’s recent Breakthrough Therapy designation further underscores AP-SA02’s clinical potential. We also appreciate the continued financial support of the U.S. Department of War (“DoW”), which comes at an important time as we prepare for this next critical stage of clinical development.”
Innventure, Inc. reported a significant net loss for the nine months ended September 30, 2026, primarily driven by a $323.5 million goodwill impairment charge. While revenue increased to $3.88 million from $1.23 million year-over-year, the company faces substantial liquidity risks and is exploring strategic alternatives for its subsidiaries AeroFlexx and Refinity.
FGI Industries reported third quarter 2026 revenue of $31.7 million, an 11.6% year-over-year decline driven by softness in housing and remodeling activity. Despite the revenue drop, gross margin expanded by 110 basis points to 27.6% due to cost discipline and product mix management, though the company recorded a net loss of $0.9 million.
“FGI reported total revenue of $31.7 million in the quarter, representing a year-over-year decline of 11.6%. The quarter reflected a challenging market environment, with continued softness in housing and remodeling activity, reduced customer purchasing and delayed projects weighing on demand across several product categories.”
Dave Bruce, CEO of FGI
“Revenue declined 11.6% year-over-year in the third quarter, reflecting softness in our core North American sanitaryware and shower system categories. Operating expenses remained disciplined, declining on a year-to-date basis, and we continued to advance our commercial pipeline and strengthen sales reporting and account-level performance tracking.”
Emerson Electric $830M Debt Financing with J.P. Morgan Securities plc
Emerson Electric Co. entered into a pricing agreement for a public offering of €750 million aggregate principal amount of 4.000% Notes due 2032. The company expects net proceeds of approximately $830.4 million, which will be used primarily to repay commercial paper borrowings and for general corporate purposes.
Xos, Inc. reported its third quarter 2026 financial results, achieving its third consecutive quarter of positive GAAP gross profit and a 17% sequential revenue increase to $5.5 million. Despite a year-over-year revenue decline, the company improved its nine-month GAAP gross margin to 26.9% and reduced operating expenses by 10% through disciplined cost management.
Codexis reported a significant increase in total revenues to $19.26 million for Q3 2026, up from $8.60 million in the prior year, driven primarily by product revenue growth. The company successfully reduced its quarterly net loss to $8.13 million compared to $19.62 million in Q3 2025, while strengthening its cash position through a $24.9 million net equity offering.
Metlife President & CEO Michel Khalaf Sells $19.3M of Stock
Michel Khalaf, President & CEO, sold 187,425 shares of Metlife Inc at $102.97 a share, worth $19.3M in total on Nov 10, 2026. Shares held after the trade: 759,013 (-19.8%).
RPM International Director Frederick R. Nance Sells $197K of Stock
Frederick R. Nance, Director, sold 1,896 shares of RPM International Inc at $103.97 a share, worth $197K in total on Nov 9, 2026. Shares held after the trade: 7,651 (-19.9%).
Rain Enhancement Technologies Holdco received a deficiency notice from Nasdaq on November 6, 2026, because its Class A common stock failed to maintain a minimum bid price of $1.00 for 30 consecutive business days. The company has until May 5, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for at least ten consecutive business days.